{"topic_id":"EU_2020_354_entry_27_osteoarthritis","category":"eu","context":"---\ntopic_id: \"EU_2020_354_entry_27_osteoarthritis\"\ncategory: \"eu\"\ntitle: \"EU 2020 354 entry 27 osteoarthritis\"\nlang: en\nsource_document: \"EU Regulation / European Commission — Reg 2020/354\"\ncitation:\n  authority: \"eu\"\n  title: \"EU 2020 354 entry 27 osteoarthritis\"\n  url: \"https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32020R0354\"\n  retrieved: \"\"\n  ref: \"Reg 2020/354\"\n  doc_type: \"official source\"\n  needs_review: false\nauthority_tier: T1\nauthority_tier_basis: \"T1:eu-law\"\nauthority_tier_date: 2026-08-04\n---\nEU Reg 2020/354 Part B Entry 27 — `Support of the metabolism of joints in the case of osteoarthritis`\n\n**Species**: Dogs, Cats\n\n**Purpose (essential nutritional characteristics)**: Support of the metabolism of joints in the case of osteoarthritis — (Dogs) Total omega-3 fatty acids ≥ 29 g per kg and eicosapentaenoic acid ≥ 3,3 g per kg complete feed with a moisture content of 12 % (2) And Adequate levels of vitamin E / (Cats) Total omega-3 fatty acids ≥ 10,6 g per kg complete feed with a moisture content of 12 % (2) and docosahexaenoic acid ≥ 2,5 g per kg complete feed with a moisture content of 12 % (2) And Increased levels of methionine and manganese Adequate levels of vitamin E.\n\n**Duration of use**: Initially up to 3 months\n\n**Source**: EU Reg 2020/354 Part B (consolidated text per EUR-Lex CELEX:02020R0354, version 2025-04-22). Entry 27 is part of the 44 PARNUT entries in Part B (range 10-72). Cross-references: AAFCO nutrition profiles for chronic kidney disease, cardiac disease, dermatological conditions. FEDIAF nutritional guidelines 2025 provide complementary guidance but do not authorize therapeutic claims — EU 2020/354 is required for products marketed with PARNUT claims.\n\n**Notes**: This entry is part of the 44-entry block (10-30 + 50-72). Entries 31-49 are not used in the current consolidated text (numbering jumps from 30 to 50). Always consult official EUR-Lex consolidated 2020/354 text when preparing EU-market petitions for products covered by Entry 27.\n","sources":["eu — EU 2020 354 entry 27 osteoarthritis"],"source":{"authority":"eu","title":"EU 2020 354 entry 27 osteoarthritis","url":"https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32020R0354","retrieved":"","ref":"Reg 2020/354","doc_type":"official source","source_document":"EU Regulation / European Commission — Reg 2020/354","verification_file":""},"source_document":"EU Regulation / European Commission — Reg 2020/354","source_file":"","trust":{"authority_tier":"T1","fidelity":"verbatim","license":null,"display_grade":"A"},"tokens_estimated":318,"generated_at":"2026-07-18","tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}